Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Use of Peripherally Inserted Central Catheter (PICC) for the Infusion of Peripheral Blood Stem Cell Products Is Safe and Effective

Shi Hui Clarice Choong, Michelle Poon, MBBS, MRCP, FRCPATH, Teck Guan Soh, Jedidah Lieow, BSc,MSN, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Yee Mei Lee, BSN, MN, PhD, Joanne Shu Xian Lee, MBBS, MRCP, Davanaliz Gonzales Ramos, Eng Soo Yap, MBBS, MMed (Int MD, MRCP, FRCPath Haematology

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141719

Published: 2020

Journal Articles

Feasibility of Advanced Practice Nurse - Led Telehealth Service in Patients with Myeloproliferative Neoplasm in the Community: A Singapore Single-Centre Report

Chi Ching Lim, BSN,MSN,RN, Xiaojuan Chen, BsN, MN, Yee Mei Lee, BsN, MN, PhD, Winnie ZY Teo, MB Bch BAO, MRCP(I), FRCPath (UK), Moon Ley Tung, BMedSci (Australia), MBBS (Australia), MRCP (UK), FRCPath (UK), Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Melissa Ooi, MB Bch, BAO, MRCP(I), FRCPath, PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-138410

Published: 2020

Journal Articles

ZRSR1 Cooperates with ZRSR2 in Regulating Splicing of U12-Type Introns in Murine Hematopoietic Cells

Zeya Cao, Vikas Madan, PhD, Weoi Woon Teoh, Pushkar Dakle, Lin Han, PhD, Pavithra Shyamsunder, Siqin Zhou, Jia Li, PhD, Hazimah Binte Mohd Nordin, Shi Jizhong, Yu Shuizhou, Henry Yang, PhD, Md Zakir Hossain, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, H. Phillip Koeffler, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-136071

Published: 2020

Journal Articles

Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Xinhua Li, Cindy Lin, Jin Seok Kim, MD PhD, Hiroshi Handa, MD PhD, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139019

Published: 2020

Journal Articles

Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma

Jianbiao Zhou, MDPhD, Sabrina Hui Min Toh, BSc, Kalpnaa Balan, BSc, Tze King Tan, PhD, Yunlu Jia, MD, Jing Quan Lim, PhD, Choon Kiat Ong, PhDBSc, Soon Thye Lim, MBBS, MRCP, Tuan Zea Tan, Siok-Bian Ng, Takaomi Sanda, MD PhD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-136244

Published: 2020

Journal Articles

Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Cindy Lin, Xinhua Li, Chandramouli Nagarajan, MBBS, Sung-Soo Yoon, MD PhD, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-139092

Published: 2020

Journal Articles

High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling

Martin H Van Vliet, Yan-Ting Chen, PhD, Erik H Van Beers, PhD, Rowan Kuiper, PhD, Erik T. Valent, PhD, Marieke Spaan, MSc, Carolina Terragna, Elena Zamagni, Michele Cavo, Stefania Oliva, Alessandra Larocca, Torsten Haferlach, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Anders Waage, MD PhD, M Duin, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-137389

Published: 2020

Journal Articles

Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients

Cinnie Yentia Soekojo, MD, Tae-Hoon Chung, Muhammad Shaheryar Furqan, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136553

Published: 2020

Journal Articles

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Chin Hin Ng, MD MRCP, Ashish Bajel, MBBS, FRACP, FRCPA, William YK Hwang, MBBS, FRCP(London), MMed(Int MD, FAMS, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Mark McHale, B.S., PhD, Chih-Yi Hsieh, MD, Hsuan-Jen Shih, MD, Nicola McIntyre, PhD, Jamie Kwek, Wei-Ling Chang, PhD, Bertil Lindmark, MD PhD

Blood (2018) 132 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2018-99-110570

Published: 2018

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Hang Quach, MDFRACP,FRCPA,MBBS, Simon J. Harrison, MBBS,MRCP,FRCPath,FRACP,PhD, Slavisa Ninkovic, MBBS FRACP FRCPA, Jane Estell, MBBS FRACP, Noemi Horvath, MBBS FRACP FRCPA, Nick Murphy, MBBS FRACP FRCPA, Richard Eek, MBCHB, Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rajeev Rajagopal, Akash Kalro, MD, Robyn Hemme, Belinda Butcher, BSc(Hons) MBiostat PhDCMPP AStat, Tracey Gerber, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Brian GM Durie, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2018) 132 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2018-99-111434

Published: 2018

Journal Articles

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Blood (2017) 130 (Supplement 1): 5386.

https://doi.org/10.1182/blood.V130.Suppl_1.5386.5386

Published: 2017

Journal Articles

Presence of Post Induction Minimal Residual Disease (MRD) Is an Independent Predictor for Relapse and Is Associated with Inferior Survival in Acute Myeloid Leukemia (AML)

Winnie ZY Teo, MRCP, MBBS, Elaine Seah, BSc, Shir Ying Lee, FRCPath,MBBS,MRCP,, Te-Chih Liu, FRCPath, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Chin Hin Ng, MD MRCP

Blood (2017) 130 (Supplement 1): 1389.

https://doi.org/10.1182/blood.V130.Suppl_1.1389.1389

Published: 2017

Journal Articles

MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia

Joseph David Khoury, MD, Ioanna Xagoraris, MD, Nikolaos Tsesmetzis, MSc., Ida Hed Hed Myrberg, PhD, Thale Kristin Olsen, Siok Bian Ng, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Benedict Yan, Chin Hin Ng, MD MRCP, Michael Andreeff, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Herold Nikolas, MD PhD, Dan Grander, MD PhD, George Rassidakis, MD PhD

Blood (2017) 130 (Supplement 1): 3964.

https://doi.org/10.1182/blood.V130.Suppl_1.3964.3964

Published: 2017

Journal Articles

Plasma LRG1 Protein Are Overexpressed in Acute Myeloid Leukemia with High Sensitivity and High Specificity in Differentiating Leukemic Plasma from Normal Plasma — a Potential Biomarker for Minimal Residual Disease Detection

Chin Hin Ng, MD MRCP, Xu Liang, PhD, Jianbiao Zhou, MD PhD, Elaine Seah, BSc, Baohong Lin, BSc, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Yoon-Pin Lim, BSc, PhD

Blood (2017) 130 (Supplement 1): 5083.

https://doi.org/10.1182/blood.V130.Suppl_1.5083.5083

Published: 2017

Journal Articles

HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML

Jerome Boyd-Kirkup, PhD, Dipti Thakkar, PhD, Peter Brauer, PhD, Jianbiao Zhou, MD PhD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Piers Jamie Ingram, PhD MBA

Blood (2017) 130 (Supplement 1): 1378.

https://doi.org/10.1182/blood.V130.Suppl_1.1378.1378

Published: 2017

NARROW

Use of Peripherally Inserted Central Catheter (PICC) for the Infusion of Peripheral Blood Stem Cell Products Is Safe and Effective

Feasibility of Advanced Practice Nurse - Led Telehealth Service in Patients with Myeloproliferative Neoplasm in the Community: A Singapore Single-Centre Report

ZRSR1 Cooperates with ZRSR2 in Regulating Splicing of U12-Type Introns in Murine Hematopoietic Cells

Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma

Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling

Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Presence of Post Induction Minimal Residual Disease (MRD) Is an Independent Predictor for Relapse and Is Associated with Inferior Survival in Acute Myeloid Leukemia (AML)

MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia

Plasma LRG1 Protein Are Overexpressed in Acute Myeloid Leukemia with High Sensitivity and High Specificity in Differentiating Leukemic Plasma from Normal Plasma — a Potential Biomarker for Minimal Residual Disease Detection

HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only